Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam
Background: Treating patients admitted to critical care with severe pneumonia requires timely intervention with an effective antibiotic. This reduces the risk of dying of pneumonia and minimises complications associated with a prolonged stay in critical care. Objective: To compare the cost-effective...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826297013597110272 |
|---|---|
| author | Edwards, S Wordsworth, S Clarke, M |
| author_facet | Edwards, S Wordsworth, S Clarke, M |
| author_sort | Edwards, S |
| collection | OXFORD |
| description | Background: Treating patients admitted to critical care with severe pneumonia requires timely intervention with an effective antibiotic. This reduces the risk of dying of pneumonia and minimises complications associated with a prolonged stay in critical care. Objective: To compare the cost-effectiveness of meropenem 1 g/8 h with piperacillin/tazobactam 4.5 g/8 h for treating pneumonia in UK critical care. Methods: A Markov model was built to estimate lifetime costs and quality-adjusted life years (QALYs) of using meropenem versus piperacillin/tazobactam to treat severe pneumonia. Estimates of effectiveness, utility weights and costs were obtained from published sources. Probabilistic sensitivity analysis was conducted to address uncertainty in the model results. Results: Cost of treating a patient with severe pneumonia was estimated as £19,026 with meropenem and £19,978 with piperacillin/tazobactam, respectively. QALYs gained were 4.768 with meropenem and 4.654 with piperacillin/tazobactam. Probabilistic sensitivity analysis showed meropenem to be consistently less costly and more effective than piperacillin/tazobactam. Conclusion: The additional efficacy of meropenem translates into more patients surviving critical care and leaving this high-cost service more quickly than if they had been treated with piperacillin/ tazobactam. As meropenem is more effective and less expensive than piperacillin/tazobactam at treating patients with severe pneumonia, it is the dominant treatment option. © 2011 Springer-Verlag. |
| first_indexed | 2024-03-07T04:25:09Z |
| format | Journal article |
| id | oxford-uuid:cc5b346e-5c9e-4e1f-8a13-2593a4e5b072 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:25:09Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:cc5b346e-5c9e-4e1f-8a13-2593a4e5b0722022-03-27T07:21:22ZTreating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactamJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cc5b346e-5c9e-4e1f-8a13-2593a4e5b072EnglishSymplectic Elements at Oxford2012Edwards, SWordsworth, SClarke, MBackground: Treating patients admitted to critical care with severe pneumonia requires timely intervention with an effective antibiotic. This reduces the risk of dying of pneumonia and minimises complications associated with a prolonged stay in critical care. Objective: To compare the cost-effectiveness of meropenem 1 g/8 h with piperacillin/tazobactam 4.5 g/8 h for treating pneumonia in UK critical care. Methods: A Markov model was built to estimate lifetime costs and quality-adjusted life years (QALYs) of using meropenem versus piperacillin/tazobactam to treat severe pneumonia. Estimates of effectiveness, utility weights and costs were obtained from published sources. Probabilistic sensitivity analysis was conducted to address uncertainty in the model results. Results: Cost of treating a patient with severe pneumonia was estimated as £19,026 with meropenem and £19,978 with piperacillin/tazobactam, respectively. QALYs gained were 4.768 with meropenem and 4.654 with piperacillin/tazobactam. Probabilistic sensitivity analysis showed meropenem to be consistently less costly and more effective than piperacillin/tazobactam. Conclusion: The additional efficacy of meropenem translates into more patients surviving critical care and leaving this high-cost service more quickly than if they had been treated with piperacillin/ tazobactam. As meropenem is more effective and less expensive than piperacillin/tazobactam at treating patients with severe pneumonia, it is the dominant treatment option. © 2011 Springer-Verlag. |
| spellingShingle | Edwards, S Wordsworth, S Clarke, M Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam |
| title | Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam |
| title_full | Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam |
| title_fullStr | Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam |
| title_full_unstemmed | Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam |
| title_short | Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam |
| title_sort | treating pneumonia in critical care in the united kingdom following failure of initial antibiotic a cost utility analysis comparing meropenem with piperacillin tazobactam |
| work_keys_str_mv | AT edwardss treatingpneumoniaincriticalcareintheunitedkingdomfollowingfailureofinitialantibioticacostutilityanalysiscomparingmeropenemwithpiperacillintazobactam AT wordsworths treatingpneumoniaincriticalcareintheunitedkingdomfollowingfailureofinitialantibioticacostutilityanalysiscomparingmeropenemwithpiperacillintazobactam AT clarkem treatingpneumoniaincriticalcareintheunitedkingdomfollowingfailureofinitialantibioticacostutilityanalysiscomparingmeropenemwithpiperacillintazobactam |